Living With Generalized Myasthenia Gravis
Living with myasthenia gravis is exhausting in a very specific way. The disease fluctuates. Muscles work, then fatigue, then recover after rest, then fail again. People describe a left eyelid that droops by late afternoon, double vision when they are tired, voice fading mid-sentence on a phone call, food getting stuck because the swallowing muscles give out halfway through dinner, arms going dead overhead while doing hair, and legs that work fine for the first block of a walk and then refuse to climb the next set of stairs.
The pattern is also the diagnostic clue. The Myasthenia Gravis Foundation of America estimates that 70,000 to 100,000 people in the United States have the disease, which puts it well under the 200,000-patient threshold the FDA uses to define a rare disease.
Understanding why this happens helps explain why Rystiggo works. The neuromuscular junction is the tiny gap where a nerve signals a muscle to move. In about 85% of generalized myasthenia gravis patients, the immune system mistakenly produces antibodies against the acetylcholine receptor (AChR), which is the docking station that catches the nerve's signal at the muscle. The antibodies block the receptor and the signal does not get through.
In another 5-10% of patients, the antibodies attack a different protein at the same junction called muscle-specific tyrosine kinase (MuSK), which produces similar weakness with a few clinical differences. A small share of patients are anti-LRP4 positive, and another group is seronegative, meaning standard tests do not detect a known antibody despite clear clinical myasthenia.
The antibody type drives which therapies are likely to work, which is why your neurologist will check your antibody status before recommending a treatment, and why Rystiggo is approved specifically for the AChR-positive and MuSK-positive subtypes.
Most patients reach Rystiggo after years of trying other things. Pyridostigmine (Mestinon) is a pill that boosts acetylcholine at the neuromuscular junction temporarily, like turning the volume up on a fading signal. It was first approved by the FDA on April 6, 1955 and is still the first thing most patients try.
Steroids like prednisone calm the immune system broadly. Steroid-sparing immunosuppressants (mycophenolate, azathioprine) take months to work but allow lower steroid doses. Rituximab depletes the B cells that produce antibodies. IVIG is donated immunoglobulin given as an infusion to dampen the immune response. Each of these helps some patients and not others, and each carries its own side-effect burden. The arrival of FcRn inhibitors in 2021 created a different kind of option, one that targets the antibody mechanism directly instead of suppressing the immune system as a whole.
What Is Rystiggo and Who Is It For?
Rystiggo is a prescription medication for generalized myasthenia gravis. The generic (chemical) name is rozanolixizumab-noli. It is made by the pharmaceutical company UCB. The FDA approved Rystiggo on June 27, 2023 for adults whose myasthenia gravis tests positive for anti-AChR or anti-MuSK antibodies, the two most common antibody types behind the disease. Rystiggo is not a steroid, not an old-style immunosuppressant, and not a complement inhibitor like Soliris. It belongs to a newer class called FcRn inhibitors, which also includes Vyvgart (efgartigimod), approved in December 2021, and Imaavy (nipocalimab), approved in April 2025.
Rystiggo is given as a subcutaneous infusion (a small needle just under the skin in the lower belly, not into a vein) once a week for six weeks. The dose depends on body weight. Adults under 50kg (about 110 pounds) receive 420mg, adults from 50 to 99kg (about 110 to 220 pounds) receive 560mg, and adults 100kg or more (about 220 pounds and up) receive 840mg. Each infusion takes about 15 minutes. After the six-week cycle, you and your neurologist decide together whether and when to do another cycle, based on how your symptoms respond and how long the benefit lasts.
Latest for Myasthenia Gravis
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
Free email alert
Want the next Myasthenia Gravis update without checking back?
We email you when a new Myasthenia Gravis trial opens or an FDA decision comes out.
You'll get trial alerts and disease updates for Myasthenia Gravis, and you can turn either off anytime. We never share your email. Privacy policy
How Rystiggo Works: FcRn Inhibition in Antibody-Mediated MG
Antibodies are proteins your immune system makes to fight infections. The most common kind, called IgG, normally lasts about 21 days in your bloodstream. The reason IgG lasts that long is a recycling protein called the neonatal Fc receptor, or FcRn. Each time an IgG antibody gets pulled into a cell, FcRn rescues it and puts it back into circulation. Without FcRn, IgG would get broken down in hours instead of weeks. The recycling system works for healthy antibodies that fight infection, and unfortunately it also works for the harmful antibodies that cause autoimmune disease.
Rystiggo blocks FcRn. With the recycling protein out of action, IgG antibodies get broken down faster than your body can replace them. Total IgG levels in the blood drop sharply over the six-week treatment cycle, and that drop includes the harmful anti-AChR or anti-MuSK antibodies driving the myasthenia.
In the MycarinG trial, mean maximum reductions from baseline were 74.7% on the 7mg/kg dose and 78.4% on the 10mg/kg dose (Bril et al., The Lancet Neurology, 2023). As the pathogenic antibodies clear out, more acetylcholine receptors at the neuromuscular junction become available, the nerve-to-muscle signal strengthens, and strength and daily function improve. The effect can usually be measured within a week or two of starting.
What sets FcRn inhibition apart from older treatments is speed and selectivity. Steroids work, but they take weeks to months to fully kick in and bring weight gain, bone loss, sleep problems, blood sugar issues, and other side effects when used for years. Mycophenolate and azathioprine can take three to six months to show benefit. Rituximab works by depleting B cells, but it can be weeks before the antibody levels drop.
Rystiggo and the other FcRn inhibitors go straight at the antibody pool, which is why MycarinG patients improved on average within the first treatment cycle. The trade-off is that the benefit fades after the last dose as IgG levels rebound, so most patients need re-treatment cycles to keep symptoms controlled. A course of rituximab, by contrast, can sometimes hold for many months.
The MG Treatment Journey: Where Rystiggo Fits
Generalized myasthenia gravis treatment has evolved in distinct waves. Pyridostigmine (Mestinon, 1955) was the first symptomatic therapy and is still the first thing most patients try. It boosts acetylcholine at the neuromuscular junction without addressing the underlying autoimmunity. Some patients do well on Mestinon alone for years; many need more.
Steroids entered the picture in the 1960s. Prednisone works to suppress the immune response, often dramatically, but the long-term toll on bone, glucose metabolism, mood, and weight makes it hard to use indefinitely. Steroid-sparing immunosuppressants (azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus) followed in the 1980s and 1990s. They allow lower steroid doses but bring their own monitoring requirements and side effects.
Plasmapheresis and IVIG arrived as rescue therapies for myasthenic crisis. Plasmapheresis physically removes antibodies from the blood. IVIG floods the system with healthy IgG, partly through FcRn-mediated mechanisms. Both work fast, both require infusion or apheresis cycles, and both are typically reserved for short-term use rather than long-term maintenance.
Targeted biologics started arriving in October 2017 with Soliris (eculizumab), the first disease-modifying drug FDA-approved for myasthenia gravis. Ultomiris (ravulizumab) followed in April 2022 as a longer-acting version of the same complement-blocking mechanism. In the US, both are approved for anti-AChR antibody-positive gMG (Soliris for adults and children 6 and older, Ultomiris for adults), with no requirement that the disease be refractory.
Rituximab depletes B cells and is used off-label for severe and refractory disease, particularly in MuSK-positive patients. The first FcRn inhibitor, Vyvgart (efgartigimod), was approved in December 2021 for anti-AChR-positive adults and was expanded in May 2026 to cover all four adult gMG serotypes (AChR+, MuSK+, LRP4+, and triple seronegative), which argenx describes as the first and only therapy approved across all subtypes.
Rystiggo followed in June 2023 as the second FcRn inhibitor, covering anti-AChR-positive and anti-MuSK-positive adults. Imaavy (nipocalimab) was approved in April 2025 as the third, covering AChR+ and MuSK+ patients ages 12 and older.
For patients who are candidates, a common question is where Rystiggo might sit in their personal sequence. Some neuromuscular specialists try FcRn inhibitors earlier in the disease, before patients accumulate years of steroid exposure. Others reserve them for refractory disease where conventional immunosuppression has failed. The right answer depends on antibody status, comorbidities, prior treatment response, insurance coverage, and how the patient tolerates a six-week subcutaneous infusion cycle. None of those decisions belongs in a blog post. The point of this section is to show where Rystiggo fits in the historical sequence, not to prescribe.
MycarinG: The Phase 3 Trial That Got Rystiggo Approved
The trial that earned Rystiggo its FDA approval is called MycarinG (study identifier NCT03971422). It was a randomized, double-blind, placebo-controlled Phase 3 study run at 81 outpatient centers across Asia, Europe, and North America. In total, 200 adults with anti-AChR-positive or anti-MuSK-positive generalized myasthenia gravis were randomly assigned to receive Rystiggo at one of two doses (7mg per kilogram or 10mg per kilogram, given as subcutaneous infusions weekly for six weeks) or a matching placebo. The full results were published in The Lancet Neurology in May 2023 by Bril and colleagues.
The trial measured improvement using a tool called the MG-ADL (Myasthenia Gravis-Activities of Daily Living) score. MG-ADL is a 0-to-24 scale where patients rate how much their disease is interfering with eight everyday activities, including talking, chewing, swallowing, breathing, brushing teeth, getting up from a chair, double vision, and eyelid drooping. Each activity is scored from 0 (no problem) to 3 (severe). Lower scores are better. A 2-point drop in the score is the smallest improvement that researchers and patients consider clinically important.
Both Rystiggo doses beat placebo by a wide margin (Bril et al., The Lancet Neurology, 2023). After six weeks, patients on the 7mg/kg dose dropped an average of 3.37 points on MG-ADL, patients on the 10mg/kg dose dropped 3.40 points, and patients on placebo dropped only 0.78 points.
The treatment difference (Rystiggo minus placebo) was -2.59 points for the 7mg/kg dose (95% CI -4.09 to -1.25) and -2.62 points for the 10mg/kg dose (95% CI -3.99 to -1.16), both larger than the 2-point threshold for a clinically important change.
Because each of the 8 items is scored from 0 to 3, a drop of about 3 points means the average patient reported less trouble with some of the everyday activities the scale tracks. Physician-administered strength tests (the QMG and MGC scales) showed parallel improvements.
“Rystiggo 7mg/kg produced a -3.37 MG-ADL change, 10mg/kg produced -3.40, and placebo produced -0.78. Both average changes were larger than the 2-point minimum clinically important difference, and the FDA approved weight-based dosing based on this trial.”
Trial Friend summary of MycarinG results (Bril et al., The Lancet Neurology, 2023)
The benefit held up in both AChR-positive and MuSK-positive patients, which is why the Rystiggo FDA label covers both antibody subtypes. At the time of approval in 2023, this set it apart from Vyvgart, which was then approved only for AChR-positive adults. Vyvgart's label was later expanded in May 2026 to cover all four gMG serotypes, narrowing the serotype-coverage gap between the two drugs.
How Fast Does Rystiggo Work? Onset, Dosing, and Treatment Cycles
In MycarinG, average MG-ADL scores began to improve as early as Day 8, after the first or second weekly infusion. Peak benefit came around Day 29 to 43, near the end of the six-week cycle. The clinical pattern matches the IgG depletion curve. Total IgG fell quickly through the cycle, the pathogenic anti-AChR and anti-MuSK antibodies fell along with it, and clinical improvement followed the antibody drop.
After the six-week cycle, IgG levels rebound and clinical benefit can fade over weeks. Re-treatment cycles are part of the treatment plan, not the exception. The label allows additional cycles based on clinical response, with the timing individualized.
Some patients need a new cycle about every 2 months, and the label says starting one sooner than 63 days after the previous cycle began has not been studied. Others go longer between cycles; in the extension study the median gap was about 98 days. The label leaves the timing of later cycles to clinical judgment, so schedules after the first cycle differ from patient to patient.
The subcutaneous administration matters for daily life. Each infusion takes about 15 minutes through a small needle in the lower belly below the navel, similar in feel to a long insulin injection rather than an IV drip. The infusion can be done in clinic, at an infusion suite, or in some practices at home with a home health nurse. The original Vyvgart formulation, by comparison, is an IV infusion that takes about an hour each session, and the newer Vyvgart Hytrulo is a shot under the skin.
Rystiggo Side Effects and Safety Profile
The most common side effects in MycarinG, seen in 1 out of 10 patients or more, were headache, infections, diarrhea, fever, allergic-type reactions, and nausea (Rystiggo prescribing information, FDA 2023). Headache was the most frequent of all, and it tended to cluster around the first infusion of each treatment cycle. In MycarinG, most headaches were mild to moderate (Bril et al.), and ways to manage them are a question for the prescribing team.
Infection risk gets the most attention from neurologists. Lowering your IgG antibodies removes some of the protection your immune system uses to fight bacterial and viral infections. The infections seen most often in the trial were upper respiratory tract infections (colds, sinus infections), COVID-19, urinary tract infections, and herpes simplex reactivation (cold sores).
Most were mild to moderate, though serious infections occurred in about 4% of patients in the trial program, including 3 fatal pneumonias, and shingles has been reported since approval. The label says to delay a Rystiggo cycle until an active infection is resolved, and if you have a history of frequent serious infections, that is worth a careful conversation with your specialist before deciding.
Vaccination status matters too. Live vaccines are typically avoided during treatment, and other vaccines may be less effective when your IgG levels are at their lowest, so the label advises reviewing needed vaccines before a new treatment cycle starts.
Two safety issues in the FDA label deserve specific attention. The first is drug-induced aseptic meningitis, an inflammation of the lining of the brain and spinal cord that is caused by a medication rather than an infection. It has been reported in some patients on Rystiggo. The warning signs are a severe headache combined with fever, a stiff neck that hurts when you bend it, sensitivity to bright light, or feeling unusually confused or drowsy. Aseptic meningitis is uncommon but serious and needs immediate medical attention.
The second is allergic-type reactions, including rash and swelling around the face or throat (angioedema), which the label says occurred anywhere from 1 day to 2 weeks after a dose, so a rash or swelling that starts days later still counts. A history of severe drug allergies is worth raising with the care team before the first cycle.
Patients commonly search for whether Rystiggo can damage the kidneys or liver, or worsen diabetes. The Rystiggo label does not list kidney or liver injury among its warnings.
The label does not list blood sugar changes among its warnings. Many patients with myasthenia have been on prednisone for years and developed steroid-related diabetes, and whether any steroid dose could change after starting Rystiggo is a question for the neurologist. If you have existing diabetes, kidney disease, or liver disease, the right plan depends on your full medication list, and is best worked out with your neurologist and your other specialists together.
Drugs Like Rystiggo: How FcRn Inhibitors and Other gMG Treatments Compare
As of November 2026, 3 FcRn inhibitors are FDA-approved for generalized myasthenia gravis. Each has distinct features, and the choice between them depends on antibody status, age, formulation preference, and insurance coverage.
| Compare | Vyvgart and Vyvgart Hytrulo | Rystiggo | Imaavy |
|---|---|---|---|
| Approved for gMG | December 2021; Hytrulo in 2023 | June 2023 | April 2025 |
| Who the label covers | Adults with any antibody type, since May 2026 | Adults who are AChR+ or MuSK+ | Ages 12 and older who are AChR+ or MuSK+ |
| How it is given | Vyvgart is a 1-hour IV infusion; Hytrulo is a shot under the skin, including a prefilled syringe for home | Infusion under the skin with a small pump | IV infusion |
| Dosing | Once a week for 4 weeks, then more cycles as needed | Once a week for 6 weeks at 420mg to 840mg by body weight, then more cycles as needed | 30mg/kg to start, then 15mg/kg every 2 weeks |
| Also approved for | CIDP (Hytrulo) | Nothing else | Warm autoimmune hemolytic anemia, ages 12 and older |
| Made by | argenx | UCB | Johnson & Johnson |
| Drug page | Efgartigimod | Rozanolixizumab | Nipocalimab |
Vyvgart, the first of the 3, was originally approved only for anti-AChR-positive adults based on the ADAPT Phase 3 trial, where 68% of efgartigimod patients met the MG-ADL responder criteria compared to 30% on placebo (Howard et al., The Lancet Neurology, 2021).
On May 8, 2026, the FDA expanded both Vyvgart and Vyvgart Hytrulo labels to cover all adult gMG serotypes (AChR+, MuSK+, LRP4+, and triple seronegative), based on the ADAPT SERON Phase 3 trial that showed a 3.35-point MG-ADL improvement at week 4 (argenx press release, May 2026). According to argenx, Vyvgart is now the first and only therapy approved across all 4 gMG serotypes.
Rystiggo covers both anti-AChR-positive and anti-MuSK-positive adults, and that MuSK-positive coverage was its main clinical advantage when it was approved in June 2023.
Imaavy reaches teenagers 12 and older and is given every 2 weeks instead of in weekly cycles, the 2 main differences from Rystiggo. The pivotal Vivacity-MG3 trial showed an MG-ADL improvement of 4.70 with nipocalimab versus 3.25 with placebo over 24 weeks (Antozzi et al., The Lancet Neurology, 2025).
No trial has compared Imaavy and Rystiggo. Imaavy's trial measured MG-ADL over 24 weeks and Rystiggo's over 6 weeks, in different patients, so the numbers cannot show that either drug works better.
Outside the FcRn class, Soliris (eculizumab) and Ultomiris (ravulizumab) target complement and are approved in the US for anti-AChR antibody-positive gMG. They work through a different mechanism, and no trial has compared them head to head with FcRn blockers. Rituximab remains an off-label option, especially for MuSK-positive disease, where some studies have shown high response rates. Comparing across classes is difficult because the trials enrolled different populations and used different endpoints, so the choice often comes down to clinical judgment, prior treatment history, and the specific antibody profile.
The Pipeline: What's Next for Myasthenia Gravis Treatment
Several drugs in late-stage development could expand the options for myasthenia gravis patients over the next few years. Some are next-generation FcRn inhibitors like Rystiggo, which their makers say aim to improve on the current options. Others go after the disease through different routes entirely.
Batoclimab is another subcutaneous FcRn inhibitor, made by Immunovant. Its Phase 3 results, announced in March 2025, showed improvement starting as early as 2 weeks, according to Immunovant. Immunovant said at the same time that it does not intend to seek approval for batoclimab in myasthenia gravis and is putting its effort into IMVT-1402 instead.
IMVT-1402 is Immunovant's next-generation FcRn inhibitor. It is designed to lower IgG without dropping albumin (a blood protein) or raising LDL cholesterol, 2 changes seen with batoclimab in earlier studies. IMVT-1402 is currently in a Phase 3 study (NCT07039916) for adults with mild-to-severe generalized myasthenia gravis. Immunovant has said it chose IMVT-1402 as its lead FcRn drug based on those earlier studies.
Telitacicept, made by RemeGen, takes a different approach. Instead of blocking IgG recycling, it shuts down two of the immune-system signals (BAFF and APRIL) that keep antibody-producing B cells alive and active. The idea is to slow the production of harmful antibodies upstream rather than removing them from circulation downstream. Phase 3 results in China showed an average MG-ADL drop of 5.74 points compared to 0.91 with placebo at week 24, and 98% of treated patients met the responder threshold. Its global Phase 3 trial, UPSTREAM MG (NCT06456580), now sponsored by Vor Biopharma, is no longer enrolling new people, according to ClinicalTrials.gov.
Earlier-stage approaches include CAR-T cell therapies (from companies like Cabaletta and Kyverna) that aim to wipe out the antibody-producing B cells for years at a time, BTK inhibitors that block a different B-cell signaling pathway, and longer-acting complement inhibitors. For patients on Rystiggo today, the field is moving fast, and how new options might fit is a fair question to bring to a neuromuscular specialist.
Cost, Coverage, and Patient Assistance for Rystiggo
UCB's pricing disclosure lists Rystiggo at $3,155.37 per mL (UCB pricing disclosure, 2025), and the dose is set by body weight, so the yearly list cost depends on weight and on how many treatment cycles a person needs. Few patients pay list price. Coverage varies by plan, and prior authorization and step therapy are common. The Rystiggo drug page keeps the current dosing, vial sizes and help-paying details in one place.
Insurance plans typically require documentation of antibody status, a confirmed gMG diagnosis from a neuromuscular specialist, and (in many plans) prior trial of conventional immunosuppression before approving FcRn inhibitor therapy. Our broader guide to clinical trial and treatment costs covers how routine medical costs are handled while you are in treatment, what insurance is required to cover, and how patient assistance programs fit in.
UCB runs the ONWARD patient support program (1-844-669-2731), which offers a dedicated Care Coordinator, a review of coverage and financial options (even if you are uninsured), copay support that may lower costs to $0 per dose for commercially insured patients, and a Patient Assistance Program that may provide Rystiggo at no cost for up to 12 months for eligible patients. The Patient Advocate Foundation, the HealthWell Foundation, and the Myasthenia Gravis Foundation of America also have copay or grant programs for myasthenia gravis patients, though fund availability varies year to year.
A practical step for patients considering Rystiggo is asking the prescribing neurologist's office to run a benefits investigation before the first cycle, ideally before the order is placed with the specialty pharmacy. Knowing the out-of-pocket cost in advance avoids the situation where treatment is approved, infusion is scheduled, and the patient discovers a four- or five-figure copay at the pharmacy counter.
A specialty pharmacy that focuses on neuromuscular drugs (Accredo, CVS Specialty, Optum Specialty Pharmacy, others) can usually run this check. If you are denied coverage on first try, our guide to appealing an insurance denial for rare disease medication walks through the steps.
One email when Myasthenia Gravis trials change or an FDA decision lands. No newsletter, no spam.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently Asked Questions About Rystiggo
What is Rystiggo used to treat?
Rystiggo (rozanolixizumab-noli) is FDA-approved to treat generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AChR) antibodies or anti-muscle-specific tyrosine kinase (MuSK) antibodies. It is not approved for ocular-only myasthenia, seronegative gMG, anti-LRP4-positive gMG, or pediatric patients.
How does Rystiggo work?
Rystiggo blocks the neonatal Fc receptor (FcRn), which normally recycles IgG antibodies and keeps them in circulation for weeks. By blocking FcRn, Rystiggo accelerates the breakdown of IgG, including the pathogenic anti-AChR or anti-MuSK antibodies that cause myasthenia gravis. In MycarinG, average daily-function scores improved within a few weeks as antibody levels fell.
How fast does Rystiggo work?
In the MycarinG Phase 3 trial, average MG-ADL scores began to improve as early as Day 8 of treatment, after the first or second weekly infusion. Peak benefit was reached around Day 29 to 43. The clinical timeline tracks the drop in IgG levels caused by FcRn blockade.
Is Rystiggo a steroid?
No, Rystiggo is not a steroid. It is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor. The drug class is called FcRn inhibitors or neonatal Fc receptor blockers. Its label does not list the bone, weight, blood sugar or mood effects known from long-term prednisone use.
What are the most common side effects of Rystiggo?
The most common side effects in MycarinG, reported in 10% or more of patients, were headache, infections, diarrhea, fever, hypersensitivity reactions, and nausea. The most common infections were upper respiratory tract infections, COVID-19, urinary tract infections, and herpes simplex (cold sore) reactivation. Two more serious concerns appear in the FDA label: drug-induced aseptic meningitis and hypersensitivity reactions, including angioedema.
What are the alternatives to Rystiggo?
FDA-approved alternatives in the same FcRn inhibitor class are Vyvgart and Vyvgart Hytrulo (efgartigimod, expanded in May 2026 to cover all four adult gMG serotypes including AChR+, MuSK+, LRP4+, and triple seronegative) and Imaavy (nipocalimab, AChR+ or MuSK+ ages 12 and older). Outside the FcRn class, the complement inhibitors Soliris (eculizumab, plus its biosimilars Bkemv and Epysqli), Ultomiris (ravulizumab) and Zilbrysq (zilucoplan) are approved for anti-AChR-positive gMG, and the B-cell therapy Uplizna (inebilizumab) was approved in December 2025 for AChR+ or MuSK+ adults. Our myasthenia gravis drug comparison lines all 7 up by antibody type, dosing and cost. Older treatments include pyridostigmine (Mestinon), prednisone, mycophenolate mofetil, azathioprine, IVIG, plasmapheresis, and rituximab (used off-label, especially for MuSK-positive disease).
How is Rystiggo different from Vyvgart?
Both are FcRn inhibitors approved for generalized myasthenia gravis. After the May 2026 Vyvgart label expansion, Vyvgart covers all four adult gMG serotypes (AChR+, MuSK+, LRP4+, and triple seronegative), while Rystiggo covers AChR+ and MuSK+ adults. Vyvgart is available as IV (one-hour infusion, weekly for four weeks per cycle) and Vyvgart Hytrulo subcutaneous (a few minutes per dose). Rystiggo is subcutaneous only, weekly for six weeks per cycle, with weight-based dosing. The choice between them depends on antibody status, formulation preference, dosing schedule, insurance coverage, and the prescriber's clinical judgment.
How is Rystiggo administered?
Rystiggo is given by a healthcare provider as a subcutaneous infusion through a small needle in the lower belly. Each infusion takes about 15 minutes. Dosing is weekly for six weeks, with weight-based dose calculation: 420mg for adults under 50kg, 560mg for 50 to 99kg, and 840mg for 100kg and above. Re-treatment cycles are scheduled based on individual clinical response, with timing individualized by the treating specialist.
Can Rystiggo cause kidney damage?
The Rystiggo label does not list kidney damage among its warnings or common side effects. Patients with kidney disease should still discuss their full medication regimen with the prescribing specialist, since infection risk and other complications may need additional monitoring.
Is Rystiggo covered by insurance?
Coverage varies by plan, and prior authorization is typically required. Insurance often requires documentation of antibody status, a confirmed gMG diagnosis from a neuromuscular specialist, and (in some plans) a prior trial of conventional immunosuppression. UCB's ONWARD program provides coverage review and copay support for eligible patients.
What is the generic name for Rystiggo?
The generic name for Rystiggo is rozanolixizumab-noli. It is sometimes written as rozanolixizumab without the suffix. The suffix is the FDA-assigned distinguishing identifier for biologics. The drug is a humanized IgG4 monoclonal antibody manufactured by UCB.
Find Active Myasthenia Gravis Trials
Whether Rystiggo turns out to be right for you depends on a conversation with a neuromuscular specialist who knows your antibody status, your treatment history, and the practical realities of your life. The point of this guide is not to push a decision in any direction. It is to give you the information to walk into that conversation prepared, with the same vocabulary your neurologist uses and a clear picture of how Rystiggo compares to the other options on the table.
If you are also interested in the drugs still in development, IMVT-1402 has a Phase 3 trial recruiting (NCT07039916), and CAR-T therapies are in earlier trials. Eligibility usually depends on antibody status, your prior treatments, and how close you live to a research center, so the answer is highly individual.
Trial Friend lists active myasthenia gravis trials in plain language, with which antibody subtypes each trial enrolls, where the sites are, and what the eligibility criteria look like in patient-friendly form. Browse active myasthenia gravis trials on Trial Friend, search by your specific antibody subtype, and see what is open near you. You are not stuck with the treatment options of five years ago, and the team you build (your neurologist, your specialty pharmacy, your patient advocacy group, and a guide like Trial Friend) can help you find what fits.